Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PR5I concomitant administration with two meningococcal C conjugate vaccines in healthy infants
2011-002413-11Phase 3Completed
- Sponsor
- Sanofi Pasteur MSD S.N.C
- Start
- Sep 2011
- Modality
- Vaccines & Immunotherapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of DTaP-IPV-Hep B-PRP-T vaccine, Meningococcal group C polysaccharide conjugate vaccine and Hib-MenC-TT in meningococcal disease, Haemophilus influenzae type b disease (Hib), diphtheria and 5 more (2 arms), sponsored by Sanofi Pasteur MSD S.N.C. Primary endpoint: Primary immunogenicity endpoint. Started Sep 2011; status: completed.
02
Drugs
DTaP-IPV-Hep B-PRP-T vaccineMeningococcal group C polysaccharide conjugate vaccineHib-MenC-TT
03
Conditions
meningococcal diseaseHaemophilus influenzae type b disease (Hib)diphtheriaTetanuspertussis
Beyond the preview
Go deeper on 2011-002413-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002413-11.